An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

Completed · Phase 2

Conditions studied: Atopic Dermatitis

In brief

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS in Patients with Atopic Dermatitis

Key facts

Study ID

NCT02932891

Run by

Sun Pharmaceutical Industries, Inc.

People needed

28

Starts

2016-08-01

Expected to finish

2017-12-12

Last updated by the study team

2018-12-07

Who can join

Age: 1 and older, up to 17. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Parent/legal guardian has signed informed consent form, which meets all criteria of current FDA regulations.

You may not qualify if…

• Females who are pregnant, nursing, planning to become pregnant during the duration of the study, or if of child-bearing potential and sexually active and not prepared to use appropriate contraceptive methods to avoid pregnancy

Where it is running

• Taro Pharmaceuticals USA Inc. — Hawthorne, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.